Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

Abstract Background Chimeric antigen receptor (CAR)-T cell therapy has been used to treat pediatric refractory or relapsed mature B-cell non-Hodgkin lymphoma (r/r MB-NHL) with significantly improved outcomes, but a proportion of patients display no response or experience relapse after treatment. To...

Full description

Bibliographic Details
Main Authors: Yang Li, Yang Liu, Keyan Yang, Ling Jin, Jing Yang, Shuang Huang, Ying Liu, Bo Hu, Rong Liu, Wei Liu, Ansheng Liu, Qinlong Zheng, Yonghong Zhang
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Cancer Cell International
Subjects:
Pediatric B-cell non-hodgkin Lymphomas
CAR-T cell therapies
Gene mutations
Online Access:https://doi.org/10.1186/s12935-023-03122-2

Internet

https://doi.org/10.1186/s12935-023-03122-2

Similar Items